ClinicalTrials.gg
CompletedNCT02257567Updated Nov 14, 2022Results posted

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

A Phase 1/2 interventional study of Bendamustine and Obinutuzumab in Lymphoma, sponsored by Hoffmann-La Roche. Completed at 62 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 253 studies testing rituximab in Lymphoma — 11 open to participants now, 17 under way, 2 of them phase 3. Rituximab · Lymphoma.

Enrollment
21st of 237
331 · median 44
Started
2014
with 3 others
Phase 1/2
24 of 253
none open now
Registered
227th of 253
by date

Among the 253 studies testing rituximab in Lymphoma, this one is the 21st largest by enrollment of the 237 interventional ones that give a count, is one of 4 that started in 2014, is one of 24 in phase 1/2, and was the 227th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

11 of the 253 studies testing rituximab in Lymphoma are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies testing rituximab in Lymphoma, or all of them as a file.
02

Study summary

This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18 weeks for participants with DLBCL and 24 weeks for participants with FL.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed FL (Grades 1, 2, or 3a) or relapsed or refractory DLBCL
  • If the participant has received prior bendamustine, response duration must have been greater than (>) 1 year (for participants who have relapse disease after a prior regimen)
  • At least one bi-dimensionally on imaging scan defined as >1.5 centimeters (cm) in its longest dimension
  • Confirmed availability of archival or freshly collected tumor tissue
  • The Phase II NF Cohorts (Arms G and H) will be required to submit tissue and pathology report for central pathology review.
  • of at least 24 weeks
  • (ECOG) performance status of 0, 1, or 2
  • Adequate hematological function unless inadequate function is due to underlying disease

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (MAbs, or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
  • to bendamustine, rituximab, or obinutuzumab
  • Prior use of any MAb, radioimmunoconjugate, or antibody-drug conjugate (ADC) within 4 weeks or 5 half-lives before Cycle 1 Day 1
  • Treatment with radiotherapy, chemotherapy, immunotherapy, therapy, or any agent for the purposes of treating cancer within 2 weeks prior to Cycle 1 Day 1
  • Ongoing use >30 mg per day prednisone or equivalent, for purposes other than lymphoma symptom control
  • Completion of stem cell transplant (SCT) within 100 days prior to Cycle 1 Day 1
  • Prior allogeneic SCT
  • Eligibility for autologous SCT
  • Grade 3b FL
  • History of transformation of indolent disease to DLBCL
  • Primary or secondary CNS lymphoma
  • Current Grade >1 peripheral neuropathy
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1 Day 1
  • Suspected or latent tuberculosis
  • Positive test results for chronic virus (HBV) infection or for virus (HCV) antibody
  • Known history of (HIV) seropositive status or known infection with human T-cell leukemia virus 1 (HTLV-1) virus
  • Women who are pregnant or lactating or who intend to become pregnant within a year of the last dose of study treatment in the rituximab cohort or within 18 months of last dose in the obinutuzumab cohort
  • Evidence of laboratory abnormalities in standard renal, hepatic, or coagulation function tests
  • Treatment with chimeric antigen receptor T-cell therapy within 100 days prior to Cycle 1, Day 1
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Arm A (Phase II Randomization): Polatuzumab+BR in FL

    Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.

    Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab

  • Active comparator
    Arm B (Phase II Randomization): BR in FL

    Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.

    Drug: Bendamustine · Drug: Rituximab

  • Experimental
    Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL

    Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.

    Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab

  • Active comparator
    Arm D (Phase II Randomization): BR in DLBCL

    Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.

    Drug: Bendamustine · Drug: Rituximab

  • Experimental
    Arm E (Phase II Expansion): Polatuzumab+BG in FL

    Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.

    Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)

  • Experimental
    Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL

    Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.

    Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)

  • Experimental
    Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL

    Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.

    Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab

  • Experimental
    Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL

    Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.

    Drug: Bendamustine · Drug: Polatuzumab vedotin (Liquid) · Drug: Rituximab

  • Experimental
    Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL

    Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.

    Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)

  • Experimental
    Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL

    Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.

    Drug: Bendamustine · Drug: Obinutuzumab · Drug: Polatuzumab vedotin (Liquid)

  • Experimental
    Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL

    In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.

    Drug: Bendamustine · Drug: Rituximab · Drug: Polatuzumab vedotin (Lyophilized)

  • Experimental
    Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL

    In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.

    Drug: Bendamustine · Drug: Rituximab · Drug: Polatuzumab vedotin (Lyophilized)

Interventions

  • Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

    Also known as: Treanda; Ribomustin; Levact

  • Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

    Also known as: GA101; Gazyva; Gazyvaro

  • Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

    Also known as: DCDS4501A

  • Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

    Also known as: Rituxan; MabThera

  • Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).

    Also known as: DCDS4501S

06

What researchers measure

Primary outcomes

  1. Phase Ib: Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).

    Time frame: From the study start up to the end of the study (up to approximately 84 months)

  2. Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

    Time frame: From Month 37 to Month 84 (up to approximately 47 months)

  3. Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin

    The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

    Time frame: Baseline up to approximately Month 24

  4. Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab

    The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

    Time frame: Baseline up to approximately Month 24

  5. Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)

    The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

    Time frame: From Month 37 to Month 84 (up to approximately 47 months)

  6. Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)

    CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  7. Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC

    CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

    Time frame: 6-8 weeks after Cycle 6, Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)

  8. Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)

    Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms\*day per milliliters.

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks

  9. Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

  10. Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

  11. Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

Secondary outcomes

  1. Phase II: Percentage of Participants With AEs

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

    Time frame: From the study start up to the end of the study (up to approximately 84 months)

  2. Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin

    The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

    Time frame: Baseline to approximately Month 24

  3. Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab

    The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

    Time frame: Baseline to approximately Month 24

  4. Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator

    CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  5. Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC

    CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  6. Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  7. Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  8. Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator

    CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  9. Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC

    CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  10. Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  11. Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)

  12. Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator

    BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

    Time frame: Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)

  13. DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC

    BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

    Time frame: Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)

  14. DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator

    DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

    Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)

  15. DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC

    DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

    Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)

  16. DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator

    PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

    Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)

  17. DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC

    PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

    Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)

  18. Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator

    CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)

  19. Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately\>liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)

  20. Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)

  21. Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator

    BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

    Time frame: Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])

  22. Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC

    BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

    Time frame: Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])

  23. Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator

    DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

    Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])

  24. Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC

    DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

    Time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])

  25. Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator

    PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

    Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])

  26. Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC

    PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

    Time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])

  27. Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator

    EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.

    Time frame: From Month 37 to Month 84 (up to approximately 47 months)

  28. Phase II NF Cohorts: Overall Survival (OS)

    OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.

    Time frame: From Month 37 to Month 84 (up to approximately 47 months)

  29. Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC

    CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)

  30. Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator

    CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)

  31. Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC

    CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)

  32. Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)

  33. Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC

    OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).

    Time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)

  34. Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE

    PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

    Time frame: Cycle 1 Day 2: pre-dose and 30 minutes (min) post dose; Cycle 1 Days 8 and 15; Cycle 2 and 4 Day 1: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)

  35. Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE

    PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.

    Time frame: Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose

  36. Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab

    PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

    Time frame: Cycle 1 Days 2: pre-dose & 30 min post dose; Cycle 1 Days 8 & 15; Cycle 2 and 4 Day 1 and unscheduled visits: pre-dose & 30 min post dose; Follow up at Day 1: Months 3, 6, 12, 18 & 24; study treatment completion visit (up to approx. 84 months)

  37. Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab

    PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.

    Time frame: Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose

  38. Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE

    PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

    Time frame: Cycle 1 Day 2: pre-dose and 30 min post dose, Cycle 1 Days 8 and 15; Cycles 2 and 4: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)

  39. Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE

    PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.

    Time frame: Cycle 1 Day 2: post dose; Cycle 1 and 3 Day 8 and 15; Cycle 2, 3 and 4 Day 1: pre-dose and post dose

  40. Plasma Concentration of Bendamustine

    Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).

    Time frame: Cycle 1 Day 2: pre-dose, 5 min, 1 hour (h); 2h, 3h and 4h post dose

  41. Serum Concentration of Rituximab

    Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).

    Time frame: Cycle 1 Days 1: pre-dose and 30 min post dose; Cycle 2 and 4 Day 1: pre-dose; unscheduled visits: pre-dose and 30 min post dose (up to approximately 84 months)

  42. Serum Concentration of Obinutuzumab

    Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

    Time frame: Cycles 1 and 4 Days 1: pre-dose and 30 min post dose; Cycle 2 Day1: pre-dose; Follow up visits on Day 1: Months 3, 6, 12, 18 and 24; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)

  43. Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  44. Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  45. Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C

    PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.

    Time frame: Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  46. Phase II: Cmax of Bendamustine and Rituximab in Arms B and D

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  47. Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F

    PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.

    Time frame: Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  48. Arm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

  49. Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day\*micrograms per milliliter \[day\*ug/mL\]).

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  50. Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  51. Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  52. Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  53. Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  54. Arm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)

    PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks

  55. Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  56. Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  57. Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  58. Phase II: CL of Bendamustine and Rituximab in Arms B and D

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  59. Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  60. Arm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

  61. Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  62. Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  63. Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  64. Phase II: Vss of Bendamustine and Rituximab in Arms B and D

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  65. Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)

  66. Arm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)

    PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

    Time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

  67. Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F

    The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.

    Time frame: Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)

07

Results

Posted Nov 14, 2022

Participant flow

A total of 331 participants with relapsed or refractory (R/R) follicular lymphoma (FL) or diffuse large B cell lymphoma (DLBCL) were enrolled in this study at 56 investigative sites in the following countries: Australia, Canada, Czech Republic, France, Germany, Hungary, Italy, Korea, the Netherlands, Spain, Turkey, United Kingdom, and the United States from 15 October 2014 to 21 October 2021.

Participant flow — Overall Study
MilestoneCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Started6666394140402021106
Safety population6666384139392020106
Completed442120226216030
Not completed22451919343842176
Withdrew: Adverse event00011000100
Withdrew: Death22241511263021865
Withdrew: Lost to follow-up00002200011
Withdrew: Not treated/per sponsor participant could not continue/pathology showed transformation: cycle 1day 100001020000
Withdrew: Physician decision00000002010
Withdrew: Withdrawal by subject002006661110

Outcome measures

PrimaryPhase Ib: Percentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).

Time frame:
From the study start up to the end of the study (up to approximately 84 months)
Reported as:
Number · percentage of participants
Phase Ib: Percentage of Participants With Adverse Events (AEs)
percentage of participantsCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL
Phase Ib: Percentage of Participants With Adverse Events (AEs)100100100100
PrimaryArm G+H (Phase II NF Cohort): Percentage of Participants With AEs

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

Time frame:
From Month 37 to Month 84 (up to approximately 47 months)
Reported as:
Number · percentage of participants
Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs
percentage of participantsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs99.1
PrimaryCohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin

The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

Time frame:
Baseline up to approximately Month 24
Reported as:
Number · percentage of participants
Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin
percentage of participantsCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL
Baseline Prevalence of ADAs50.033.3
Post-Baseline Incidence of ADAs033.3
PrimaryCohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab

The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

Time frame:
Baseline up to approximately Month 24
Reported as:
Number · percentage of participants
Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
percentage of participantsCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL
Baseline Prevalence of ADAs to Polatuzumab vedotin00
Post-Baseline Incidence of ADAs to Polatuzumab vedotin00
Baseline Prevalence of ADAs to Obinutuzumab00
Post-Baseline Incidence of ADA to Obinutuzumab00
PrimaryArms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)

The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

Time frame:
From Month 37 to Month 84 (up to approximately 47 months)
Reported as:
Number · percentage of participants
Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)
percentage of participantsArm G (Phase II NF Cohort): Pola+BR in DLBCLArm H (Phase II NF Cohort): Pola+BR in DLBCL
Baseline Prevalence of ADAs to Polatuzumab0.01.6
Post-Baseline Incidence of ADAs to Polatuzumab2.65.0
PrimaryPhase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)

CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)69.2 (52.43 to 82.98)63.4 (46.94 to 77.88)42.5 (27.04 to 59.11)17.5 (7.34 to 32.78)39.6 (30.25 to 49.59)
Statistical analysis
  • Arm A (Phase II Randomization): Pola+BR in FL vs Arm B (Phase II Randomization): BR in FL · Cochran-Mantel-Haenszel · p = 0.5353 · Difference in response rates: 5.82 · 95% CI -14.53 to 25.38
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0128 · Difference in response rates (4.89: 25.00 · 95% CI 4.89 to 42.63
PrimaryArm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC

CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

Time frame:
6-8 weeks after Cycle 6, Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Reported as:
Number · percentage of participants
Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
percentage of participantsArm H (Phase II NF Cohort): Pola+BR in DLBCL
Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC42.2 (29.94 to 55.18)
PrimaryArm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)

Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms\*day per milliliters.

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks
Reported as:
Geometric mean · ng*day/mL
Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)
ng*day/mLArm G (Phase II NF Cohort): Pola+BR in DLBCL
acMMAE2880 ± 0.15
MMAE21.6 ± 45
PrimaryArm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
Reported as:
Geometric mean · nanograms per milliliters (ng/mL)
Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)
nanograms per milliliters (ng/mL)Arm G (Phase II NF Cohort): Pola+BR in DLBCL
acMMAE724 ± 10
MMAE2.01 ± 38
PrimaryArm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

No measurements were reported for this outcome.

PrimaryArm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

No measurements were reported for this outcome.

SecondaryPhase II: Percentage of Participants With AEs

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

Time frame:
From the study start up to the end of the study (up to approximately 84 months)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With AEs
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With AEs10010010097.410010099.1
SecondaryArms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin

The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

Time frame:
Baseline to approximately Month 24
Reported as:
Number · percentage of participants
Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCL
Baseline Prevalence of ADAs00
Post-Baseline Incidence of ADAs7.92.9
SecondaryArms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab

The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.

Time frame:
Baseline to approximately Month 24
Reported as:
Number · percentage of participants
Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
percentage of participantsArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Baseline Prevalence of ADAs to Polatuzumab00
Post-Baseline Incidence of ADAs to Polatuzumab5.35.6
Baseline Prevalence of ADAs to Obinutuzumab00
Post-Baseline Incidence of ADAs to Obinutuzumab00
SecondaryPhase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator

CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator64.1 (47.18 to 78.80)63.4 (46.94 to 77.88)42.5 (27.04 to 59.11)15.0 (5.71 to 29.84)65.0 (40.78 to 84.61)33.3 (14.59 to 56.97)36.8 (27.63 to 46.71)
Statistical analysis
  • Arm A (Phase II Randomization): Pola+BR in FL vs Arm B (Phase II Randomization): BR in FL · Cochran-Mantel-Haenszel · p = 0.8817 · Difference in response rates: 0.69 · 95% CI -19.68 to 20.86
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0061 · Difference in response rates: 27.50 · 95% CI 7.66 to 44.74
SecondaryPhase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC

CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
percentage of participantsArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G (Phase II Expansion): Pola+BR in DLBCL
Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC65.0 (40.78 to 84.61)33.3 (14.59 to 56.97)35.7 (21.55 to 51.97)
SecondaryPhase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator79.5 (63.54 to 90.70)80.5 (63.13 to 91.18)47.5 (31.51 to 63.87)17.5 (7.34 to 32.78)85.0 (62.11 to 96.79)33.3 (14.59 to 56.97)42.5 (32.91 to 52.43)
Statistical analysis
  • Arm A (Phase II Randomization): Pola+BR in FL vs Arm B (Phase II Randomization): BR in FL · Cochran-Mantel-Haenszel · p = 0.9523 · Difference in response rates: -1.00 · 95% CI -18.66 to 16.46
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0036 · Difference in response rates: 30.00 · 95% CI 9.48 to 47.37
SecondaryPhase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC76.9 (60.67 to 88.87)73.2 (57.06 to 85.78)42.5 (27.04 to 59.11)17.5 (7.34 to 32.78)85.0 (62.11 to 96.79)38.1 (18.11 to 61.56)43.4 (33.80 to 53.37)
Statistical analysis
  • Arm A (Phase II Randomization): Pola+BR in FL vs Arm B (Phase II Randomization): BR in FL · Cochran-Mantel-Haenszel · p = 0.6574 · Difference in response rates: 3.75 · 95% CI -15.14 to 22.11
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0128 · Difference in response rates: 25.00 · 95% CI 4.89 to 42.63
SecondaryPhase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator

CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator46.2 (30.09 to 62.82)19.5 (8.82 to 34.87)20.0 (9.05 to 35.65)5.0 (0.61 to 16.92)20.0 (5.73 to 43.66)14.3 (3.05 to 36.34)14.2 (8.14 to 22.26)
SecondaryPhase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC

CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC41.0 (25.57 to 57.90)36.6 (22.12 to 53.06)22.5 (10.84 to 38.45)2.5 (0.06 to 13.16)50.0 (27.20 to 72.80)23.8 (8.22 to 47.17)17.9 (11.15 to 26.57)
SecondaryPhase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator79.5 (63.54 to 90.70)75.6 (59.70 to 87.64)45.0 (29.26 to 61.51)15.0 (5.71 to 29.84)80.0 (56.34 to 94.27)33.3 (14.59 to 56.97)42.5 (32.91 to 52.43)
Statistical analysis
  • Arm A (Phase II Randomization): Pola+BR in FL vs Arm B (Phase II Randomization): BR in FL · Cochran-Mantel-Haenszel · p = 0.6225 · Difference in response rates: 3.88 · 95% CI -14.49 to 21.72
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0032 · Difference in response rates: 30.00 · 95% CI 9.94 to 47.12
SecondaryPhase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC74.4 (57.87 to 86.96)80.5 (65.13 to 91.18)40.0 (24.86 to 56.67)15.0 (5.71 to 29.84)80.0 (56.34 to 94.27)38.1 (18.11 to 61.56)41.5 (32.02 to 51.49)
Statistical analysis
  • Arm A (Phase II Randomization): Pola+BR in FL vs Arm B (Phase II Randomization): BR in FL · Cochran-Mantel-Haenszel · p = 0.4835 · Difference in response rates: -6.13 · 95% CI -24.14 to 12.12
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0096 · Difference in response rates: 25.00 · 95% CI 5.39 to 42.33
SecondaryPhase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator

BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

Time frame:
Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator
percentage of participantsArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator89.7 (75.78 to 97.13)90.2 (76.87 to 97.28)70.0 (53.47 to 83.44)32.5 (18.57 to 49.13)90.0 (68.30 to 98.77)52.4 (29.78 to 74.29)62.3 (52.33 to 71.50)
Statistical analysis
  • Arm A (Phase II Randomization): Pola+BR in FL vs Arm B (Phase II Randomization): BR in FL · Cochran-Mantel-Haenszel · p = 0.9390 · Difference in response rates: -0.50 · 95% CI -15.07 to 13.71
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0006 · Difference in response rates: 37.50 · 95% CI 15.64 to 54.71
SecondaryDLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC

BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN \& ELS, score=4 or 5, reduced UT than baseline (BL) \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

Time frame:
Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)
Reported as:
Number · percentage of participants
DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC
percentage of participantsArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC62.5 (45.80 to 77.27)25.0 (12.69 to 41.20)42.9 (21.82 to 65.98)57.5 (47.57 to 67.09)
Statistical analysis
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Cochran-Mantel-Haenszel · p = 0.0005 · Difference in response rates: 37.50 · 95% CI 15.82 to 54.62
SecondaryDLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator

DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

Time frame:
From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)
Reported as:
Median · months
DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator
monthsArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator12.665 (5.782 to 27.926)4.074 (2.563 to 12.682)16.099 (2.825 to 27.860)11.335 (6.242 to 16.197)
Statistical analysis
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Log Rank · p = 0.0245 · Hazard ratio (hr): 0.42 · 95% CI 0.19 to 0.91
SecondaryDLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC

DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

Time frame:
From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)
Reported as:
Median · months
DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC
monthsArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC10.908 (5.684 to 40.674)10.645 (3.975 to 19.647)25.758 (9.692 to 46.752)13.437 (8.641 to 20.041)
Statistical analysis
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Log Rank · p = 0.2451 · Hazard ratio (hr): 0.60 · 95% CI 0.25 to 1.43
SecondaryDLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator

PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

Time frame:
From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)
Reported as:
Median · months
DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator
monthsArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator7.491 (4.928 to 16.953)2.037 (1.544 to 3.713)5.125 (2.103 to 18.234)5.881 (4.764 to 7.524)
Statistical analysis
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Log Rank · p = <.0001 · Hazard ratio (hr): 0.33 · 95% CI 0.20 to 0.56
SecondaryDLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC

PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

Time frame:
From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)
Reported as:
Median · months
DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC
monthsArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC9.248 (6.045 to 13.930)3.713 (2.070 to 4.534)5.848 (2.103 to 11.893)6.965 (5.092 to 9.823)
Statistical analysis
  • Arm C (Phase II Randomization): Pola+BR in DLBCL vs Arm D (Phase II Randomization): BR in DLBCL · Log Rank · p = 0.0003 · Hazard ratio (hr): 0.39 · 95% CI 0.23 to 0.66
SecondaryPhase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator

CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Reported as:
Number · percentage of participants
Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
percentage of participantsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator36.8 (27.63 to 46.71)
SecondaryPhase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately\>liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Reported as:
Number · percentage of participants
Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator
percentage of participantsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator42.5 (32.91 to 52.43)
SecondaryPhase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Reported as:
Number · percentage of participants
Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
percentage of participantsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC43.4 (33.80 to 53.37)
SecondaryPhase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator

BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

Time frame:
Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])
Reported as:
Number · percentage of participants
Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator
percentage of participantsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator62.3 (52.33 to 71.50)
SecondaryPhase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC

BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes \& ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT markedly higher than liver \&/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes \& ELS, score=4 or 5, reduced UT than BL \& residual mass of any size;residual UT\>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi \& no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes \& extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.

Time frame:
Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])
Reported as:
Number · percentage of participants
Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC
percentage of participantsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC57.5 (47.57 to 67.09)
SecondaryPhase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator

DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

Time frame:
From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])
Reported as:
Median · months
Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator
monthsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator11.335 (6.242 to 16.197)
SecondaryPhase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC

DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT\> background; 2=UT≤mediastinum;3=UT\>mediastinum but ≤liver;4=UT moderately\>liver;5=UT\>than liver \&/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL \& residual mass of any size at interim for LN \& ELS;residual UT\>UT in normal bone marrow but\<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN \& ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.

Time frame:
From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])
Reported as:
Median · months
Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC
monthsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC13.437 (8.641 to 20.041)
SecondaryPhase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator

PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

Time frame:
From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])
Reported as:
Median · months
Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator
monthsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator5.881 (4.764 to 7.524)
SecondaryPhase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC

PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.

Time frame:
From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])
Reported as:
Median · months
Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC
monthsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC6.965 (5.092 to 9.823)
SecondaryPhase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator

EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.

Time frame:
From Month 37 to Month 84 (up to approximately 47 months)
Reported as:
Median · months
Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator
monthsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator5.092 (4.402 to 6.867)
SecondaryPhase II NF Cohorts: Overall Survival (OS)

OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.

Time frame:
From Month 37 to Month 84 (up to approximately 47 months)
Reported as:
Median · months
Phase II NF Cohorts: Overall Survival (OS)
monthsArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Phase II NF Cohorts: Overall Survival (OS)12.320 (8.279 to 16.986)
SecondaryArm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC

CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Reported as:
Number · percentage of participants
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
percentage of participantsArm G (Phase II NF Cohort): Pola+BR in DLBCL
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC35.7 (21.55 to 51.97)
SecondaryArm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator

CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Reported as:
Number · percentage of participants
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
percentage of participantsArm G (Phase II NF Cohort): Pola+BR in DLBCL
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator9.5 (2.66 to 22.62)
SecondaryArm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC

CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
Reported as:
Number · percentage of participants
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
percentage of participantsArm G (Phase II NF Cohort): Pola+BR in DLBCL
Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC14.3 (5.43 to 28.54)
SecondaryArm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)
Reported as:
Number · percentage of participants
Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
percentage of participantsArm G (Phase II NF Cohort): Pola+BR in DLBCL
Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator38.1 (23.57 to 54.36)
SecondaryArm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC

OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).

Time frame:
6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)
Reported as:
Number · percentage of participants
Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
percentage of participantsArm G (Phase II NF Cohort): Pola+BR in DLBCL
Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC33.3 (19.57 to 49.55)
SecondaryPlasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE

PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

Time frame:
Cycle 1 Day 2: pre-dose and 30 minutes (min) post dose; Cycle 1 Days 8 and 15; Cycle 2 and 4 Day 1: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
ng/mLCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Cycle 1 Day 2: Pre-doseNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Cycle 1 Day 2: 30 min Post Dose654 ± 29.3617 ± 26.2719 ± 26.7718 ± 14.2492 ± 241.6643 ± 24.7453 ± 682.8472 ± 617.2
Cycle 1 Day 829.4 ± 5887.275.9 ± 40.890.7 ± 46.1109 ± 48.2————
Cycle 1 Day 1512.2 ± 1626.925.4 ± 29.828.9 ± 48.634.4 ± 37.3————
Cycle 2 Day 1: Pre-dose3.21 ± 546.512.4 ± 47.98.75 ± 77.716.6 ± 25.64.72 ± 159.812.7 ± 120.59.05 ± 74.413.1 ± 45.2
Cycle 2 Day 1: 30 min Post Dose685 ± 22.0683 ± 20.1803 ± 20.1834 ± 13.5————
Cycle 4 Day 1: Pre-dose12.2 ± 26.121.1 ± 46.715.3 ± 61.926.2 ± 22.111.2 ± 109.320.7 ± 46.415.2 ± 30.519.6 ± 30.5
Cycle 4 Day 1: 30 min Post Dose748 ± 23.4754 ± 14.4734 ± 22.0716 ± 13.7689 ± 20.9645 ± 21.4829 ± 20.3709 ± 10.1
Unscheduled Visit—————41.1 ± 49.453.0 ± 58.0—
Unscheduled Visit: Pre-dose————1.21 ± NA0.180 ± NA——
Unscheduled Visit: 30 min Post Dose—————915 ± NA——
Study Treatment Completion——18.7 ± NA—10.7 ± 181.714.2 ± 95.714.9 ± 69.412.3 ± 109.4
SecondaryArm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE

PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.

Time frame:
Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose
Reported as:
Mean · ng/mL
Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
ng/mLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Cycle 1 Day 2: Post Dose653 ± 237
Cycle 2 Day 1: Pre-dose14.6 ± 8.66
Cycle 2 Day 1: Post Dose667 ± 155
Cycle 4 Day 1: Pre-dose23.2 ± 8.59
Cycle 4 Day 1: Post Dose659 ± 156
SecondarySerum Concentration of of Polatuzumab Vedotin Analyte: Total Ab

PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

Time frame:
Cycle 1 Days 2: pre-dose & 30 min post dose; Cycle 1 Days 8 & 15; Cycle 2 and 4 Day 1 and unscheduled visits: pre-dose & 30 min post dose; Follow up at Day 1: Months 3, 6, 12, 18 & 24; study treatment completion visit (up to approx. 84 months)
Reported as:
Geometric mean · grams per milliliters (g/mL)
Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
grams per milliliters (g/mL)Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Cycle 1 Day 2: Pre-doseNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Cycle 1 Day 2: 30 min Post Dose33.2 ± 28.436.6 ± 25.437.5 ± 29.134.3 ± 20.335.4 ± 27.734.6 ± 26.232.4 ± 22.838.3 ± 20.3
Cycle 1 Day 83.43 ± 4393.49.01 ± 43.710.2 ± 39.310.0 ± 31.9————
Cycle 1 Day 151.83 ± 1784.34.26 ± 35.34.61 ± 40.65.22 ± 28.4————
Cycle 2 Day 1: Pre-dose0.696 ± 941.22.31 ± 54.22.20 ± 76.13.70 ± 27.41.23 ± 203.12.48 ± 137.62.20 ± 100.62.83 ± 41.8
Cycle 2 Day 1: 30 min Post Dose35.8 ± 25.939.5 ± 28.343.4 ± 31.142.2 ± 22.9————
Cycle 4 Day 1: Pre-dose3.44 ± 30.55.03 ± 59.04.61 ± 62.26.26 ± 18.33.61 ± 97.85.72 ± 39.94.82 ± 20.85.03 ± 29.3
Cycle 4 Day 1: 30 min Post Dose40.2 ± 27.244.6 ± 11.043.0 ± 25.847.1 ± 24.244.8 ± 24.340.6 ± 20.655.0 ± 21.337.5 ± 11.6
Follow up on Month 3, Day 10.164 ± 51.90.771 ± 193.40.910 ± 82.80.394 ± 27.10.265 ± 209.90.316 ± 266.20.489 ± 174.20.543 ± 126.7
Follow up on Month 6, Day 10.0250 ± 0.00.0788 ± 230.00.219 ± 96.60.104 ± 18.50.0539 ± 145.70.0564 ± 195.70.0920 ± 123.50.150 ± 206.6
Follow up on Month 12, Day 10.0250 ± 0.00.0250 ± 0.00.0298 ± 35.90.0250 ± 0.00.0250 ± 0.00.0301 ± 60.60.0250 ± 0.00.0250 ± 0.0
Follow up on Month 18, Day 10.0250 ± 0.00.0250 ± 0.00.0250 ± 0.00.0250 ± 0.00.0250 ± 0.0—0.0250 ± 0.00.0250 ± 0.0
Follow up on Month 24, Day 10.0250 ± 0.00.0250 ± 0.00.0250 ± NA0.0250 ± NA———0.0250 ± NA
Unscheduled Visit0.0250 ± 0.00.0250 ± 0.0—0.0250 ± NA—1.65 ± 5419.81.23 ± 30267.8—
Unscheduled Visit: Pre-dose————0.279 ± NA0.0250 ± NA——
Unscheduled Visit: 30 min Post Dose—————42.0 ± NA——
Study Treatment Completion Visit——5.34 ± NA—3.34 ± 180.54.33 ± 69.44.57 ± 57.23.23 ± 79.3
SecondaryArm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab

PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.

Time frame:
Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose
Reported as:
Mean · ng/mL
Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab
ng/mLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Cycle 1 Day 2: Post Dose33.9 ± 11.7
Cycle 2 Day 1: Pre-dose3.27 ± 4.37
Cycle 2 Day 1: Post Dose36.0 ± 8.71
Cycle 4 Day 1: Pre-dose5.41 ± 1.79
Cycle 4 Day 1: Post Dose39.2 ± 7.30
SecondaryPlasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE

PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

Time frame:
Cycle 1 Day 2: pre-dose and 30 min post dose, Cycle 1 Days 8 and 15; Cycles 2 and 4: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
ng/mLCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Cycle 1 Day 2: Pre-doseNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Cycle 1 Day 2: 30 min Post Dose0.726 ± 297.50.234 ± 80.20.397 ± 67.70.327 ± 41.40.402 ± 80.20.315 ± 105.30.243 ± 101.80.456 ± 103.1
Cycle 1 Day 81.48 ± 100.81.84 ± 78.41.96 ± 51.52.34 ± 21.4————
Cycle 1 Day 150.311 ± 93.80.531 ± 88.50.705 ± 60.00.688 ± 19.5————
Cycle 2 Day 1: Pre-dose0.0264 ± 70.80.158 ± 79.40.0512 ± 129.30.150 ± 44.40.0373 ± 81.50.159 ± 80.90.0451 ± 76.90.186 ± 86.8
Cycle 2 Day 1: 30 min Post Dose0.185 ± 54.20.263 ± 72.70.231 ± 53.50.345 ± 31.9————
Cycle 4 Day 1: Pre-dose0.0414 ± 102.90.133 ± 72.60.0511 ± 68.30.150 ± 44.30.0554 ± 77.30.158 ± 58.20.0481 ± 83.20.141 ± 102.3
Cycle 4 Day 1: 30 min Post Dose0.234 ± 35.00.266 ± 27.00.167 ± 39.20.257 ± 32.30.198 ± 32.00.316 ± 38.90.195 ± 38.10.283 ± 56.9
Unscheduled Visit——————0.738 ± 64.6—
Unscheduled Visit: Pre-dose————0.0180 ± NA0.0180 ± NA——
Unscheduled Visit: 30 min Post Dose—————0.114 ± NA——
Study Treatment Completion——0.0595 ± NA—0.0506 ± 113.00.0749 ± 165.90.0682 ± 110.40.150 ± 179.4
SecondaryArm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE

PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.

Time frame:
Cycle 1 Day 2: post dose; Cycle 1 and 3 Day 8 and 15; Cycle 2, 3 and 4 Day 1: pre-dose and post dose
Reported as:
Mean · ng/mL
Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
ng/mLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
Cycle 1 Day 2: Post Dose0.590 ± 1.08
Cycle 2 Day 1: Pre-dose0.229 ± 0.248
Cycle 2 Day 1: Post Dose0.316 ± 0.213
Cycle 4 Day 1: Pre-dose0.186 ± 0.118
Cycle 4 Day 1: Post Dose0.256 ± 0.118
SecondaryPlasma Concentration of Bendamustine

Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).

Time frame:
Cycle 1 Day 2: pre-dose, 5 min, 1 hour (h); 2h, 3h and 4h post dose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Bendamustine
ng/mLCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Cycle 1 Day 2: Pre-dose————NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Cycle 1 Day 2: 5 min Post Dose————2130 ± 665.62810 ± 222.72740 ± 550.91700 ± 1865.53090 ± 68.33790 ± 119.4
Cycle 1 Day 2: 1h Post Dose————456 ± 167.8353 ± 187.9518 ± 154.2451 ± 380.2478 ± 111.4639 ± 165.6
Cycle 1 Day 2: 2h Post Dose————84.4 ± 173.555.1 ± 236.593.8 ± 250.5101 ± 375.862.8 ± 104.3128 ± 196.7
Cycle 1 Day 2: 3h Post Dose————20.5 ± 220.112.7 ± 246.423.5 ± 461.021.5 ± 509.912.4 ± 132.028.2 ± 287.4
Cycle 1 Day 2: 4h Post Dose————7.60 ± 278.54.58 ± 268.48.11 ± 724.88.08 ± 615.93.30 ± 147.26.18 ± 131.0
SecondarySerum Concentration of Rituximab

Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).

Time frame:
Cycle 1 Days 1: pre-dose and 30 min post dose; Cycle 2 and 4 Day 1: pre-dose; unscheduled visits: pre-dose and 30 min post dose (up to approximately 84 months)
Reported as:
Geometric mean · ng/mL
Serum Concentration of Rituximab
ng/mLCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCL
Cycle 1 Days 1: Pre-dose——NA ± NANA ± NANA ± NANA ± NA
Cycle 1 Days 1: 30 min Post Dose——182 ± 27.2202 ± 24.5188 ± 19.9180 ± 18.0
Cycle 2 Days 1: Pre-dose——22.8 ± 79.220.2 ± 145.934.9 ± 89.934.6 ± 69.7
Cycle 4 Days 1: Pre-dose——65.1 ± 46.562.3 ± 42.774.7 ± 50.983.3 ± 49.1
Unscheduled: Pre-dose——30.6 ± 118.0—298 ± NA2.00 ± NA
Unscheduled: 30 min Post Dose—————165 ± NA
SecondarySerum Concentration of Obinutuzumab

Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.

Time frame:
Cycles 1 and 4 Days 1: pre-dose and 30 min post dose; Cycle 2 Day1: pre-dose; Follow up visits on Day 1: Months 3, 6, 12, 18 and 24; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
Reported as:
Geometric mean · g/mL
Serum Concentration of Obinutuzumab
g/mLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Cycle 1 Day 1: Pre-doseNA ± NANA ± NANA ± NANA ± NA
Cycle 1 Day 1: 30 min Post Dose——341 ± 22.1221 ± 105.5
Cycle 2 Day 1: Pre-dose283 ± 38.4412 ± 40.8301 ± 39.3349 ± 58.0
Cycle 4 Day 1: Pre-dose293 ± 53.8359 ± 28.9291 ± 37.9290 ± 36.4
Cycle 4 Day 1: 30 min Post Dose——701 ± 27.4642 ± 29.5
Follow up on Month 3, Day 167.7 ± 47.828.8 ± 17.038.5 ± 167.855.1 ± 119.9
Follow up on Month 6, Day 111.5 ± 56.65.38 ± 12.47.64 ± 412.215.8 ± 137.6
Follow up on Month 12, Day 10.237 ± 717.60.389 ± 119.30.162 ± 569.70.732 ± 18.7
Follow up on Month 18, Day 10.00978 ± 1188.50.0107 ± 170.50.00842 ± 347.40.0460 ± 86.9
Follow up on Month 24, Day 10.00203 ± NA0.00203 ± NA—0.00203 ± NA
Unscheduled—3.09 ± NA20.8 ± NA—
Unscheduled Visit: Pre-dose———0.0626 ± NA
Unscheduled Visit: 30 min Post Dose———349 ± NA
Study Treatment Completion Visit367 ± NA—242 ± 52.7232 ± 46.2
SecondaryPhase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Mean · ng/mL
Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
ng/mLCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL
acMMAE: Cycle 1676 ± 176634 ± 158
acMMAE: Cycle 2697 ± 129694 ± 138
acMMAE: Cycle 4763 ± 159759 ± 107
Total Ab: Cycle 134.3 ± 8.5737.6 ± 9.42
Total Ab: Cycle 236.6 ± 8.0040.6 ± 9.46
Total Ab: Cycle 441.3 ± 9.9844.8 ± 5.06
Unconjugated MMAE: Cycle 13.31 ± 4.002.21 ± 1.34
SecondaryPhase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Mean · ng/mL
Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
ng/mLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL
acMMAE: Cycle 1738 ± 165725 ± 104
acMMAE: Cycle 2816 ± 168841 ± 115
acMMAE: Cycle 4749 ± 158721 ± 97.7
Total Ab: Cycle 138.7 ± 9.8434.9 ± 7.52
Total Ab: Cycle 245.0 ± 12.143.1 ± 9.52
Total Ab: Cycle 444.2 ± 11.248.2 ± 12.5
Unconjugated MMAE: Cycle 12.17 ± 1.082.39 ± 0.492
SecondaryPhase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C

PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.

Time frame:
Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Mean · ng/mL
Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
ng/mLArm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCL
acMMAE: Cycle 1622 ± 194661 ± 149
acMMAE: Cycle 4703 ± 150659 ± 135
Total Ab: Cycle 136.7 ± 9.5435.7 ± 8.50
Total Ab: Cycle 446.1 ± 11.441.4 ± 8.29
Bendamustine: Cycle 13.57 ± 2.064.23 ± 2.26
Rituximab: Cycle 1188 ± 49.2191 ± 35.9
SecondaryPhase II: Cmax of Bendamustine and Rituximab in Arms B and D
Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Mean · ug/mL
Phase II: Cmax of Bendamustine and Rituximab in Arms B and D
ug/mLArm B (Phase II Randomization): BR in FLArm D (Phase II Randomization): BR in DLBCL
Bendamustine3.21 ± 2.093.85 ± 2.91
Rituximab207 ± 50.1183 ± 33.6
SecondaryPhase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F

PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.

Time frame:
Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Mean · ug/mL
Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F
ug/mLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
acMMAE: Cycle 1692 ± 230703 ± 211
acMMAE: Cycle 4845 ± 165713 ± 70.6
Total Ab: Cycle 133.3 ± 8.0439.0 ± 7.63
Total Ab: Cycle 456.1 ± 11.237.8 ± 4.51
Bendamustine: Cycle 13.30 ± 1.585.47 ± 4.30
Obinutuzumab: Cycle 1349 ± 72.8274 ± 118
Obinutuzumab: Cycle 4727 ± 217666 ± 190
SecondaryArm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

No measurements were reported for this outcome.

SecondaryPhase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day\*micrograms per milliliter \[day\*ug/mL\]).

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · day*ug/mL
Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
day*ug/mLCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL
acMMAE2830 ± 12.12110 ± 28.4
Total Ab298 ± 4.9214 ± 35.9
SecondaryPhase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · day*ug/mL
Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
day*ug/mLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL
acMMAE2600 ± 34.42650 ± 16.4
Total Ab267 ± 30.2252 ± 21.6
SecondaryPhase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · h*ug/mL
Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
h*ug/mLArm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCL
Bendamustine3.29 ± 73.33.62 ± 78.5
SecondaryPhase II: AUCinf of Bendamustine and Rituximab in Arms B and D
Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · h*ug/mL
Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D
h*ug/mLArm B (Phase II Randomization): BR in FLArm D (Phase II Randomization): BR in DLBCL
Bendamustine2.86 ± 67.33.43 ± 97.4
SecondaryPhase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · h*ug/mL
Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F
h*ug/mLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Bendamustine2.88 ± 28.94.10 ± 67.4
SecondaryArm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)

PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks

No measurements were reported for this outcome.

SecondaryPhase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · mL/day/kg
Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
mL/day/kgCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL
acMMAE11.3 ± 12.915.2 ± 27.9
Total Ab6.05 ± 4.78.48 ± 35.2
SecondaryPhase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · mL/day/kg
Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
mL/day/kgCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL
acMMAE12.3 ± 34.912.1 ± 17.0
Total Ab6.76 ± 30.67.17 ± 22.2
SecondaryPhase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · Liters per hour (L/h)
Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
Liters per hour (L/h)Arm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCL
Bendamustine47.9 ± 60.842.6 ± 66.4
SecondaryPhase II: CL of Bendamustine and Rituximab in Arms B and D
Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · L/h
Phase II: CL of Bendamustine and Rituximab in Arms B and D
L/hArm B (Phase II Randomization): BR in FLArm D (Phase II Randomization): BR in DLBCL
Bendamustine54.4 ± 60.946.4 ± 93.9
SecondaryPhase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · L/h
Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
L/hArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Bendamustine61.3 ± 33.439.9 ± 76.1
SecondaryArm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

No measurements were reported for this outcome.

SecondaryPhase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · mL/kg
Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a
mL/kgCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL
acMMAE73.0 ± 22.382.7 ± 33.2
Total Ab82.3 ± 9.176.6 ± 25.7
SecondaryPhase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Mean · mL/kg
Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
mL/kgCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL
acMMAE77.2 ± 38.864.7 ± 23.0
Total Ab87.5 ± 38.587.9 ± 24.7
SecondaryPhase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · L
Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
LArm A (Phase II Randomization): Pola+BR in FLArm C (Phase II Randomization): Pola+BR in DLBCL
Bendamustine36.5 ± 86.434.3 ± 57.7
SecondaryPhase II: Vss of Bendamustine and Rituximab in Arms B and D
Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · L
Phase II: Vss of Bendamustine and Rituximab in Arms B and D
LArm B (Phase II Randomization): BR in FLArm D (Phase II Randomization): BR in DLBCL
Bendamustine44.9 ± 69.633.2 ± 62.9
SecondaryPhase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
Reported as:
Geometric mean · L
Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
LArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Bendamustine51.2 ± 33.631.5 ± 68.1
SecondaryArm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)

PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.

Time frame:
Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks

No measurements were reported for this outcome.

SecondarySymptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F

The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.

Time frame:
Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)
Reported as:
Mean · Points on scale
Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
Points on scaleArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCL
Baseline0.2 ± 0.30.5 ± 1.10.4 ± 0.60.6 ± 0.70.8 ± 1.6—
Week 10.3 ± 0.4———0.0 ± NA—
Week 20.3 ± 0.40.5 ± 1.30.3 ± 0.41.0 ± 1.10.2 ± 0.2—
Week 30.2 ± 0.50.7 ± 1.50.1 ± 0.10.9 ± 0.10.0 ± 0.1—
Week 40.1 ± 0.20.8 ± 1.80.3 ± 0.30.7 ± 0.80.2 ± 0.4—
Week 50.2 ± 0.30.6 ± 1.40.3 ± 0.50.6 ± 0.60.1 ± 0.2—
Week 60.2 ± 0.40.8 ± 1.80.3 ± 0.50.7 ± 1.00.1 ± 0.3—
Week 70.3 ± 0.40.9 ± 1.90.2 ± 0.30.4 ± 0.60.0 ± 0.1—
Week 80.3 ± 0.40.8 ± 1.80.2 ± 0.50.6 ± 0.90.2 ± 0.4—
Week 90.4 ± 0.90.5 ± 0.90.2 ± 0.30.5 ± 0.70.1 ± 0.3—
Week 100.5 ± 0.90.4 ± 0.80.1 ± 0.10.2 ± 0.40.1 ± 0.2—
Week 110.5 ± 1.00.5 ± 0.90.2 ± 0.20.4 ± 0.60.1 ± 0.1—
Week 120.5 ± 1.40.9 ± 2.00.3 ± 0.40.3 ± 0.60.2 ± 0.2—
Week 130.7 ± 1.20.6 ± 1.60.3 ± 0.40.2 ± 0.40.3 ± 0.4—
Week 140.6 ± 1.20.7 ± 1.80.3 ± 0.30.4 ± 0.60.2 ± 0.4—
Week 150.2 ± 0.30.7 ± 1.70.4 ± 0.50.4 ± 0.40.9 ± 1.6—
Week 160.4 ± 0.50.8 ± 1.80.4 ± 0.40.4 ± 0.50.3 ± 0.7—
Week 170.2 ± 0.30.8 ± 1.80.5 ± 0.70.4 ± 0.60.3 ± 0.5—
Week 180.2 ± 0.30.7 ± 1.80.3 ± 0.40.1 ± 0.10.3 ± 0.5—
Week 190.2 ± 0.30.8 ± 2.00.4 ± 0.70.5 ± 0.80.3 ± 0.5—
Week 200.0 ± 0.20.8 ± 1.90.6 ± 0.80.1 ± 0.10.3 ± 0.4—
Week 210.3 ± 0.30.9 ± 1.90.5 ± 0.50.1 ± 0.10.3 ± 0.3—
Week 220.2 ± 0.20.8 ± 2.00.9 ± 1.50.0 ± NA0.5 ± 0.6—
Week 230.2 ± 0.30.8 ± 2.20.6 ± 0.70.0 ± NA0.5 ± 0.6—
Week 240.4 ± 0.61.0 ± 2.30.5 ± 0.70.0 ± 0.10.3 ± 0.3—
Week 250.2 ± 0.20.2 ± 0.20.3 ± 0.40.0 ± NA0.1 ± 0.1—
Week 260.6 ± 0.83.3 ± 4.40.4 ± 0.60.0 ± NA——
Week 270.3 ± 0.31.1 ± 2.50.5 ± 0.60.1 ± 0.10.4 ± 0.4—
Week 280.5 ± 0.61.2 ± 2.60.5 ± 0.70.0 ± NA0.1 ± 0.2—
Week 290.2 ± 0.20.8 ± 2.10.7 ± 0.70.0 ± NA0.1 ± 0.2—
Week 300.7 ± 1.10.7 ± 1.90.8 ± 0.80.0 ± NA0.1 ± 0.1—
Week 310.3 ± 0.30.0 ± 0.11.3 ± 0.90.0 ± NA0.1 ± 0.1—
Week 320.4 ± 0.40.1 ± 0.11.0 ± 0.9—0.2 ± 0.3—
Week 330.3 ± 0.30.1 ± 0.21.0 ± 1.0—0.2 ± 0.2—
Week 340.2 ± 0.21.3 ± 2.40.8 ± 0.5—0.2 ± 0.3—
Week 350.3 ± 0.30.0 ± NA1.2 ± 0.70.6 ± 0.90.4 ± NA—
Week 360.5 ± 0.30.2 ± 0.31.2 ± 0.6—0.1 ± 0.2—
Week 370.4 ± 0.40.1 ± 0.11.1 ± 0.8—0.2 ± 0.3—
Week 380.4 ± 0.40.1 ± NA1.5 ± 0.4—0.3 ± NA—
Week 390.7 ± 0.90.0 ± NA1.5 ± 0.50.0 ± NA0.3 ± NA—
Week 400.5 ± 0.40.0 ± NA0.9 ± 0.4—0.1 ± 0.2—
Week 410.6 ± 0.60.7 ± 1.61.4 ± 1.2—0.3 ± 0.4—
Week 420.5 ± 0.50.0 ± NA0.3 ± NA—0.5 ± NA—
Week 430.3 ± 0.40.0 ± NA0.6 ± NA0.0 ± NA0.4 ± NA—
Week 441.6 ± NA0.0 ± NA0.2 ± 0.3—0.7 ± NA—
Week 450.8 ± 0.70.1 ± 0.21.0 ± 1.2—0.3 ± 0.4—
Week 461.1 ± 0.70.1 ± NA0.2 ± NA—0.5 ± NA—
Week 470.4 ± 0.60.0 ± NA0.1 ± NA—0.8 ± NA—
Week 48—0.8 ± 0.90.2 ± 0.2—0.6 ± NA—
Week 490.6 ± 0.60.0 ± 0.01.1 ± 1.4—0.3 ± 0.4—
Week 501.0 ± 0.20.1 ± NA0.2 ± NA—0.5 ± NA—
Week 510.1 ± 0.20.0 ± NA0.2 ± NA—0.5 ± NA—
Week 520.4 ± NA0.4 ± 0.50.2 ± NA—0.5 ± NA—
Week 530.2 ± NA0.7 ± 1.50.2 ± NA—0.2 ± 0.3—
Week 540.8 ± 0.60.0 ± NA0.2 ± NA—0.5 ± NA—
Week 550.3 ± 0.50.2 ± NA0.2 ± NA—0.5 ± NA—
Week 560.6 ± 0.30.2 ± NA0.0 ± 0.1———
Week 570.3 ± NA0.0 ± 0.01.5 ± 2.1—0.2 ± 0.3—
Week 580.7 ± 0.6—0.0 ± NA—0.6 ± NA—
Week 590.0 ± 0.10.0 ± NA0.0 ± NA—0.6 ± NA—
Week 600.4 ± NA—0.0 ± NA———
Week 610.4 ± 0.30.3 ± 0.51.5 ± 2.1—0.3 ± 0.5—
Week 620.7 ± 1.0—0.0 ± NA—0.6 ± NA—
Week 630.4 ± 0.70.0 ± NA0.0 ± NA—0.8 ± NA—
Week 640.4 ± NA1.1 ± NA0.1 ± 0.2—0.7 ± NA—
Week 650.2 ± 0.00.0 ± 0.00.8 ± 1.3—0.0 ± NA—
Week 660.6 ± 0.7—0.0 ± NA—0.8 ± NA—
Week 670.2 ± 0.3—0.0 ± NA—0.9 ± NA—
Week 68——0.0 ± NA—1.2 ± NA—
Week 690.2 ± NA0.3 ± 0.51.5 ± 2.1—0.0 ± NA—
Week 700.7 ± 1.0—0.0 ± NA—1.0 ± NA—
Week 710.1 ± 0.1—0.0 ± NA—0.8 ± NA—
Week 72—1.2 ± NA0.0 ± NA—0.9 ± NA—
Week 730.4 ± 0.30.0 ± 0.01.3 ± 1.8—0.0 ± NA—
Week 741.3 ± 0.7—0.0 ± NA—0.8 ± NA—
Week 750.2 ± 0.0—0.0 ± NA—1.1 ± NA—
Week 76——0.7 ± NA—0.6 ± NA—
Week 77——1.5 ± NA—0.9 ± NA—
Week 780.7 ± NA—1.4 ± NA———
Week 79——1.4 ± NA—0.8 ± NA—
Week 800.0 ± NA—1.1 ± NA—0.8 ± NA—
Week 81——0.6 ± NA———
Week 82——0.6 ± NA———
Week 83——0.6 ± NA—0.8 ± NA—
Week 840.0 ± NA—0.6 ± NA———
Week 85——0.6 ± NA—0.6 ± NA—
Week 860.6 ± NA—0.6 ± NA—0.6 ± NA—
Week 89————0.7 ± NA—
Week 900.7 ± NA———0.7 ± NA—
Week 91————0.7 ± NA—
Week 92————0.7 ± NA—
Week 93————0.7 ± NA—
Week 94——0.0 ± NA—0.7 ± NA—
Week 95——0.5 ± NA—0.7 ± NA—
Week 96——0.0 ± NA—0.8 ± NA—
Week 97————0.7 ± NA—
Week 98——0.0 ± NA—0.7 ± NA—
Week 99——0.1 ± NA—0.7 ± NA—
Week 100——0.3 ± NA—0.7 ± NA—
Week 101————0.7 ± NA—
Week 102——0.2 ± NA—0.7 ± NA—
Week 103——0.3 ± NA—0.7 ± NA—
Week 104——0.2 ± NA—0.7 ± NA—
Week 105——0.1 ± NA—0.8 ± NA—
Week 107————0.7 ± NA—
Week 108————0.7 ± NA—
End of Treatment0.4 ± 0.60.6 ± 1.80.5 ± 0.80.8 ± 1.00.1 ± 0.2—

Adverse events

Collected over From Baseline up to study completion/discontinuation (up to approximately 84 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL2/6 (33.3%)2/6 (33.3%)6/6 (100%)
Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL2/6 (33.3%)4/6 (66.7%)6/6 (100%)
Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL2/6 (33.3%)4/6 (66.7%)6/6 (100%)
Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL4/6 (66.7%)5/6 (83.3%)6/6 (100%)
Arm A (Phase II Randomization): Pola+BR in FL16/39 (41%)25/38 (65.8%)38/38 (100%)
Arm B (Phase II Randomization): BR in FL11/41 (26.8%)12/41 (29.3%)39/41 (95.1%)
Arm C (Phase II Randomization): Pola+BR in DLBCL26/40 (65%)24/39 (61.5%)36/39 (92.3%)
Arm D (Phase II Randomization): BR in DLBCL30/40 (75%)27/39 (69.2%)37/39 (94.9%)
Arm E (Phase II Expansion): Pola+BG in FL3/20 (15%)8/20 (40%)20/20 (100%)
Arm F (Phase II Expansion): Pola+BG in DLBCL18/21 (85.7%)13/20 (65%)19/20 (95%)
Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL65/106 (61.3%)57/106 (53.8%)103/106 (97.2%)
Most frequent serious events
Showing 10 of 164
Most frequent serious events
EventCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
PNEUMONIAInfections and infestations0/61/60/62/67/381/414/394/390/200/206/106
SEPSISInfections and infestations0/60/62/60/61/381/412/392/390/201/207/106
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/60/60/61/66/381/414/394/392/202/209/106
ATRIAL FIBRILLATIONCardiac disorders1/60/60/60/60/380/411/390/390/201/202/106
NAUSEAGastrointestinal disorders0/60/60/61/60/380/410/390/390/200/201/106
PYREXIAGeneral disorders0/61/60/61/62/381/410/395/390/202/207/106
HEPATIC CIRRHOSISHepatobiliary disorders0/60/61/60/60/380/410/390/390/200/200/106
CLOSTRIDIAL SEPSISInfections and infestations0/61/60/60/60/380/410/390/390/200/200/106
INFECTED LYMPHOCELEInfections and infestations0/60/61/60/60/380/410/390/390/200/200/106
LARGE INTESTINE INFECTIONInfections and infestations0/60/60/61/60/380/410/390/390/200/200/106
Most frequent other events
Showing 10 of 254
Most frequent other events
EventCohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCL
NAUSEAGastrointestinal disorders3/63/65/63/622/3813/4116/3912/3911/2011/2034/106
VOMITINGGastrointestinal disorders2/61/65/61/67/388/415/397/398/208/2017/106
CONSTIPATIONGastrointestinal disorders3/61/64/62/610/388/418/397/397/209/2020/106
DIARRHOEAGastrointestinal disorders2/62/64/64/616/389/4111/3916/3910/2011/2036/106
FATIGUEGeneral disorders4/64/63/62/616/3813/4114/3914/3913/2012/2022/106
NEUTROPENIABlood and lymphatic system disorders2/60/62/61/616/3811/4114/3921/396/206/2035/106
CHILLSGeneral disorders1/61/63/62/60/383/413/394/392/205/202/106
DECREASED APPETITEMetabolism and nutrition disorders3/62/62/63/610/385/418/3910/396/208/2027/106
HYPOKALAEMIAMetabolism and nutrition disorders1/63/62/62/65/384/413/394/393/205/2015/106
HYPOMAGNESAEMIAMetabolism and nutrition disorders1/62/61/63/64/381/414/391/394/201/2013/106

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized, whether or not the participants received the assigned treatment.

Age, Continuous
Age, Continuous(years)Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCLTotal
Median68.0 (54 to 73)65.0 (58 to 79)63.5 (42 to 73)71.0 (53 to 84)65.0 (37 to 74)63.0 (39 to 80)67.0 (33 to 86)71.0 (30 to 84)60.5 (37 to 86)65.0 (26 to 86)70.0 (24 to 94)67.0 (24 to 94)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCLTotal
Female422118231215101054151
Male244521182825101152180
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCLTotal
American Indian or Alaska Native000000010001
Asian1100126416830
Native Hawaiian or Other Pacific Islander000000000000
Black or African American000010302017
White556633332631161583259
More than one race000000000000
Unknown or Not Reported00004654101434
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FLCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCLCohort 1b (Phase Ib Safety Run-In): Pola+BG in FLCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCLArm A (Phase II Randomization): Pola+BR in FLArm B (Phase II Randomization): BR in FLArm C (Phase II Randomization): Pola+BR in DLBCLArm D (Phase II Randomization): BR in DLBCLArm E (Phase II Expansion): Pola+BG in FLArm F (Phase II Expansion): Pola+BG in DLBCLArm G+H (Phase II NF Cohort): Pola+BR in DLBCLTotal
Hispanic or Latino0000131132314
Not Hispanic or Latino666634343536161987285
Not Stated00002331001322
Unknown0000211210310
08

Study locations

62 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Univ of Colorado Canc Ctr
    Aurora, Colorado 80045, United States
  • Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
    Jacksonville, Florida 32256, United States
  • Emory Univ Winship Cancer Inst
    Atlanta, Georgia 30322, United States
  • Joliet Oncology-Hematology; Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Horizon Oncology Research, Inc.
    Lafayette, Indiana 47905, United States
  • Weinberg CA Inst Franklin Sq
    Baltimore, Maryland 21237, United States
  • Regional Cancer Care Associates LLC - Morristown
    Morristown, New Jersey 07962, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87131, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • West Clinic
    Germantown, Tennessee 38138, United States
  • Swedish Cancer Inst.
    Seattle, Washington 98104, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • Prince of Wales Hospital; Oncology
    Randwick, New South Wales 2031, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Adelaide Cancer Centre
    Kurralta Park, South Australia 5037, Australia
  • Monash Medical Centre; Haematology Research
    Clayton, Victoria 3168, Australia
  • BCCA-Vancouver Cancer Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Queen Elizabeth II Health Sciences Centre; Oncology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Hopital Maisonneuve- Rosemont; Oncology
    Montreal, Quebec H1T 2M4, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultní nemocnice Ostrava Klinika hematoonkologie
    Ostrava, 70852, Czechia
  • I Interni klinika; Vseobecna fakultni nemocnice
    Prague 2, 128 08, Czechia
  • Chu Site Du Bocage;Hematologie Clinique
    Dijon, 21079, France
  • Centre Hospitalier Departemental Les Oudairies
    La Roche Sur Yon, 85925, France
  • Centre Leon Berard; Departement Oncologie Medicale
    Lyon, 69373, France
  • CHU Saint Eloi; Service d'Hématologie Clinique
    Montpellier, 34295, France
  • CHU Lyon Sud - Service Hématologie
    Pierre Benite, 69310, France
  • Centre Henri Becquerel; Hematologie
    Rouen, 76038, France
  • HELIOS Klinikum Erfurt - Innere Medizin - 4. Medizinische Klinik, Hämatologie
    Erfurt, 99089, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Abt. für Hämatologie und Onkologie
    Mainz, 55131, Germany
  • Joh. Wesling Klinikum Minden; Klinik fuer Hämatologie und Onkologie
    Minden, 32429, Germany
  • Gemeinschaftspraxis für Hämatologie und Onkologie
    Münster, 48153, Germany
  • Klinik der Uni Regensburg; Hämatologie/Onkologie, Studienzentrale
    Regensburg, 93053, Germany
  • Semmelweis University, First Dept of Medicine
    Budapest, 1083, Hungary
  • National Institute of Oncology, A Dept of Internal Medicine
    Budapest, 1122, Hungary
  • University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B
    Debrecen, 4032, Hungary
  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica
    Napoli, Campania 80131, Italy
  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
    Brescia, Lombardia 25123, Italy
  • Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia
    Milano, Lombardia 20141, Italy
  • Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia
    Alessandria, Piemonte 15121, Italy
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • UMC St. Radboud; Hematology
    Nijmegen, 6525 GA, Netherlands
  • Hospital Universitari Vall d'Hebron; Servicio de Hematologia
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial de Barcelona; Hematology
    Barcelona, 08036, Spain
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • Hospital Clinico Universitario de Salamanca;Servicio de Hematologia
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia
    Sevilla, 41013, Spain
  • Ankara University; Hematology
    Ankara, 06620, Turkey
  • Dokuz Eylul Uni ; Hematology
    Izmir, 35100, Turkey
  • Ondokuzmayis University Medical Faculty Heamatology Department
    Samsun, 55139, Turkey
  • Karadeniz Technical Uni School of Medicine; Hematology
    Trabzon, 61800, Turkey
  • KINGS COLLEGE HOSPITAL; Commercial R&D Amendments, Kings Health Partners Clinical Trials Office
    London, SE1 9RT, United Kingdom
  • Christie Hospital Nhs Trust; Medical Oncology
    Manchester, M2O 4BX, United Kingdom
  • Nottingham City Hospital; Dept of Haematology
    Nottingham, NG5 1PB, United Kingdom
  • Southampton General Hospital; Somers Cancer Research Building
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Herrera AF, Tracy S, Croft B, Opat S, Ray J, Lovejoy AF, Musick L, Paulson JN, Sehn LH, Jiang Y. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Adv. 2022 Mar 22;6(6):1651-1660. doi: 10.1182/bloodadvances.2021006415. PubMed 35086141 ↗
  • Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, Salles G, Ku G, Hirata J, Chang YM, Musick L, Matasar MJ. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794. PubMed 34749395 ↗
  • Betts KA, Thuresson PO, Felizzi F, Du EX, Dieye I, Li J, Schulz M, Masaquel AS. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. J Comp Eff Res. 2020 Oct;9(14):1003-1015. doi: 10.2217/cer-2020-0057. Epub 2020 Oct 8. Erratum In: J Comp Eff Res. 2021 Mar;10(4):337. doi: 10.2217/cer-2020-0057c1. PubMed 33028076 ↗
  • Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8. PubMed 32770353 ↗
  • Lu T, Gibiansky L, Li X, Li C, Shi R, Agarwal P, Hirata J, Miles D, Chanu P, Girish S, Jin JY, Lu D. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2020 Dec;61(12):2905-2914. doi: 10.1080/10428194.2020.1795154. Epub 2020 Jul 24. PubMed 32705923 ↗
  • Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. PubMed 31693429 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Oct 2021, 84 months.

Results were first posted in Nov 2022, 1 year after primary completion.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's 84 months is above that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 6, 2014
StartActual
Oct 15, 2014
Primary completionActual
Oct 21, 2021
CompletionActual
Oct 21, 2021
Results first posted
Nov 14, 2022
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02257567
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 6, 2014
Start date
Oct 15, 2014
Primary completion
Oct 21, 2021
Completion
Oct 21, 2021
Results posted
Nov 14, 2022
Last update
Nov 14, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polatuzumab vedotin · Rituximab

Start the discussion